News & Media

Traditional clinical trials have long imposed significant recruitment and infrastructure burdens on researchers and patients, with frustratingly slow results. This master protocol will allow multiple enrollees to be tested once and assigned to a treatment likely to work for them, rather than separate tests for separate trials with most patients ineligible. This strategy will validate biomarkers and facilitate drug development in one infrastructure, to more rapidly provide safer and more effective treatments to patients.